MSLN-CAR-T 细胞中开关受体 PD1/IL15Rβ 的表达克服实体瘤中的 PD1/PDL1 信号

Expression of the switch receptor PD1/IL15Rβ in MSLN-CAR-T cells overcomes PD1/PDL1 signaling in solid tumors.

用于无创检测间皮素过表达肿瘤的 (89)Zr 标记特异性抗体片段的构建

Construction of a (89)Zr-Labeled Specific Antibody Fragment for the Noninvasive Detection of Mesothelin-Overexpressing Tumors.

剪切应力机械预处理增强 CAR-T 细胞的记忆形成与抗肿瘤功能

Mechanical preconditioning by shear stress enhances memory formation and anti-tumor function of CAR-T cells.

Rab5 通过减少自相残杀并维持表面 CAR 水平改善 CAR-T 细胞疗效

Rab5 improves CAR T cell efficacy via reducing fratricide and maintaining surface CAR levels.

将靶向间皮素的 CAR-T 细胞导向实体瘤

Directing mesothelin-targeted chimeric antigen receptor T cells to solid tumors.

CAR-T 细胞治疗临床试验全景与发展趋势的全球多维分析

A global multidimensional analysis of the chimeric antigen receptor T-cell therapy clinical trial landscape and development trends.

更正：纳豆激酶驱动的肿瘤微环境重塑增强 MSLN 靶向 CAR-T 细胞治疗实体瘤的疗效

Correction: Nattokinase-driven remodeling of tumor microenvironment enhances the efficacy of MSLN-targeted CAR-T cell therapy in solid tumors.

MMP3 过表达增强 CAF 富集实体瘤模型中 CAR-T 细胞的浸润与抗肿瘤活性

MMP3 overexpression enhances CAR-T cell infiltration and antitumor activity in a CAF-enriched solid tumor model.

这些发现提示，MMP3 工程化是一种简单而有效的策略，可克服基质屏障并增强 CAR-T 细胞疗法在实体瘤中的疗效。

用 TCR 模拟抗体工程化 T 细胞进行三特异性靶向以限制抗原逃逸

Trispecific targeting of T cells engineered with TCR mimic antibodies to limit antigen escape.

靶向 WT1 肽/HLA-A2 复合物的免疫蛋白酶体依赖性和非依赖性表位的三特异性 T 细胞，加上识别第三种肿瘤相关抗原的 CSR，提供了一种有效且经济高效的方法来克服肿瘤免疫逃逸。

CCR2/CXCR6 增强 MSLN CAR-T 细胞的肿瘤浸润与抗肿瘤疗效

CCR2/CXCR6 enhances tumor infiltration and antitumor efficacy of MSLN CAR-T cells.